{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:38:00Z","timestamp":1783417080821,"version":"3.54.6"},"reference-count":65,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T00:00:00Z","timestamp":1470268800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Genome Canada (CA)"},{"name":"Innovacorp"},{"DOI":"10.13039\/100007670","name":"Dalhousie Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010786","name":"Genome Atlantic","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010786","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009989","name":"Nova Scotia Research Innovation Trust","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009989","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000194","name":"Nova Scotia Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000194","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canadian Institutes of Health Research (CA)"},{"DOI":"10.13039\/501100009415","name":"IWK Health Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009415","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007831","name":"Capital Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0158320","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T17:44:38Z","timestamp":1470332678000},"page":"e0158320","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["Fzd4 Haploinsufficiency Delays Retinal Revascularization in the Mouse Model of Oxygen Induced Retinopathy"],"prefix":"10.1371","volume":"11","author":[{"given":"Michael H.","family":"Ngo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Borowska-Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Godfrey","family":"Heathcote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Nejat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"McMaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johane M.","family":"Robitaille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,4]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2010.07.003","article-title":"The Norrin\/Frizzled4 signaling pathway in retinal vascular development and disease","volume":"16","author":"X Ye","year":"2010","journal-title":"Trends in molecular medicine"},{"issue":"Suppl 1","key":"ref2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"H Blencowe","year":"2013","journal-title":"Pediatric research"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1001\/archophthalmol.2012.2118","article-title":"Correlation of recognition visual acuity with posterior retinal structure in advanced retinopathy of prematurity","volume":"130","author":"DK Wallace","year":"2012","journal-title":"Archives of ophthalmology"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1442-200x.2001.01361.x","article-title":"Retinopathy of prematurity: mutations in the Norrie disease gene and the risk of progression to advanced stages","volume":"43","author":"MZ Haider","year":"2001","journal-title":"Pediatr Int"},{"issue":"Pt 2","key":"ref5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/eye.1992.32","article-title":"The premature retina: a model for the in vivo study of molecular genetics?","volume":"6","author":"JT Flynn","year":"1992","journal-title":"Eye"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1423-0127-17-69","article-title":"Genetic susceptibility to advanced retinopathy of prematurity (ROP)","volume":"17","author":"BS Shastry","year":"2010","journal-title":"Journal of biomedical science"},{"issue":"1\u20134","key":"ref7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00183127","article-title":"Dominant exudative vitreoretinopathy and other vascular developmental disorders of the peripheral retina","volume":"54","author":"CE van Nouhuys","year":"1982","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/bjo.64.2.112","article-title":"Autosomal dominant exudative vitreoretinopathy","volume":"64","author":"RR Ober","year":"1980","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/archopht.1976.03910040034006","article-title":"Fluorescein angiographic findings in familial exudative vitreoretinopathy","volume":"94","author":"CL Canny","year":"1976","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archopht.1971.01000010152007","article-title":"Familial exudative vitreoretinopathy. An expanded view","volume":"86","author":"J Gow","year":"1971","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0002-9394(99)00003-3","article-title":"Familial exudative vitreoretinopathy mimicking persistent hyperplastic primary vitreous","volume":"127","author":"A Chang-Godinich","year":"1999","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"ref12","first-page":"40","article-title":"Falciform retinal fold as sign of familial exudative vitreoretinopathy","volume":"27","author":"M Nishimura","year":"1983","journal-title":"Jpn J Ophthalmol"},{"issue":"3","key":"ref13","first-page":"221","article-title":"Juvenile retinal detachment as a complication of familial exudative vitreoretinopathy","volume":"86","author":"CE van Nouhuys","year":"1989","journal-title":"Fortschr Ophthalmol"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/BF00947005","article-title":"Familial exudative vitreoretinopathy: surgical intervention and visual acuity outcomes","volume":"235","author":"A Shubert","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/humu.20191","article-title":"Complexity of the genotype-phenotype correlation in familial exudative vitreoretinopathy with mutations in the LRP5 and\/or FZD4 genes","volume":"26","author":"M Qin","year":"2005","journal-title":"Hum Mutat"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0002-9394(14)76893-X","article-title":"Signs, complications, and platelet aggregation in familial exudative vitreoretinopathy","volume":"111","author":"CE van Nouhuys","year":"1991","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/ng957","article-title":"Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy","volume":"32","author":"J Robitaille","year":"2002","journal-title":"Nat Genet"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/bjo.2010.190116","article-title":"The role of Frizzled-4 mutations in familial exudative vitreoretinopathy and Coats disease","volume":"95","author":"JM Robitaille","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.cell.2009.07.048","article-title":"TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4\/beta-catenin signaling","volume":"139","author":"HJ Junge","year":"2009","journal-title":"Cell"},{"issue":"2","key":"ref20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajhg.2010.01.012","article-title":"Mutations in TSPAN12 cause autosomal-dominant familial exudative vitreoretinopathy","volume":"86","author":"JA Poulter","year":"2010","journal-title":"American journal of human genetics"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ajhg.2009.12.016","article-title":"Next-generation sequencing of a 40 Mb linkage interval reveals TSPAN12 mutations in patients with familial exudative vitreoretinopathy","volume":"86","author":"K Nikopoulos","year":"2010","journal-title":"American journal of human genetics"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1086\/425080","article-title":"Autosomal recessive familial exudative vitreoretinopathy is associated with mutations in LRP5","volume":"75","author":"X Jiao","year":"2004","journal-title":"Am J Hum Genet"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/hmg\/1.7.461","article-title":"Mutations in the candidate gene for Norrie disease","volume":"1","author":"W Berger","year":"1992","journal-title":"Hum Mol Genet"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng0692-204","article-title":"Isolation and characterization of a candidate gene for Norrie disease","volume":"1","author":"ZY Chen","year":"1992","journal-title":"Nat Genet"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1442-9071.2006.01314.x","article-title":"Mutations in the NDP gene: contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity","volume":"34","author":"JL Dickinson","year":"2006","journal-title":"Clin Experiment Ophthalmol"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/ng1092-139","article-title":"Norrie disease is caused by mutations in an extracellular protein resembling C-terminal globular domain of mucins","volume":"2","author":"A Meindl","year":"1992","journal-title":"Nat Genet"},{"issue":"24","key":"ref27","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1073\/pnas.1220864110","article-title":"ZNF408 is mutated in familial exudative vitreoretinopathy and is crucial for the development of zebrafish retinal vasculature","volume":"110","author":"RW Collin","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2015-306878","article-title":"KIF11 mutations are a common cause of autosomal dominant familial exudative vitreoretinopathy","volume":"100","author":"H Hu","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamaophthalmol.2014.2814","article-title":"Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by KIF11 mutations","volume":"132","author":"JM Robitaille","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"ref30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/archopht.1997.01100150653015","article-title":"Identification of missense mutations in the Norrie disease gene associated with advanced retinopathy of prematurity","volume":"115","author":"BS Shastry","year":"1997","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s100380170085","article-title":"Insertion and deletion mutations in the dinucleotide repeat region of the Norrie disease gene in patients with advanced retinopathy of prematurity","volume":"46","author":"M Hiraoka","year":"2001","journal-title":"J Hum Genet"},{"issue":"4","key":"ref32","first-page":"365","article-title":"A C597\u2014>A polymorphism in the Norrie disease gene is associated with advanced retinopathy of prematurity in premature Kuwaiti infants","volume":"9","author":"MZ Haider","year":"2002","journal-title":"Journal of biomedical science"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.1136\/jmg.38.12.e46","article-title":"De novo mutations in the 5' regulatory region of the Norrie disease gene in retinopathy of prematurity","volume":"38","author":"SJ Talks","year":"2001","journal-title":"J Med Genet"},{"key":"ref34","first-page":"501","article-title":"Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity","volume":"11","author":"KA Hutcheson","year":"2005","journal-title":"Mol Vis"},{"key":"ref35","first-page":"2572","article-title":"Genetic screening of Wnt signaling factors in advanced retinopathy of prematurity","volume":"16","author":"M Hiraoka","year":"2010","journal-title":"Mol Vis"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/13816810903479834","article-title":"Severe retinopathy of prematurity associated with FZD4 mutations","volume":"31","author":"A Ells","year":"2010","journal-title":"Ophthalmic genetics"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1399-0004.2005.00408.x","article-title":"Genetic variants of frizzled-4 gene in familial exudative vitreoretinopathy and advanced retinopathy of prematurity","volume":"67","author":"ML MacDonald","year":"2005","journal-title":"Clin Genet"},{"key":"ref38","first-page":"476","article-title":"Genetic variants of FZD4 and LRP5 genes in patients with advanced retinopathy of prematurity","volume":"19","author":"H Kondo","year":"2013","journal-title":"Molecular vision"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2009.07.047","article-title":"Norrin, frizzled-4, and Lrp5 signaling in endothelial cells controls a genetic program for retinal vascularization","volume":"139","author":"X Ye","year":"2009","journal-title":"Cell"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0092-8674(04)00216-8","article-title":"Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair","volume":"116","author":"Q Xu","year":"2004","journal-title":"Cell"},{"issue":"13","key":"ref41","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1523\/JNEUROSCI.21-13-04761.2001","article-title":"Progressive cerebellar, auditory, and esophageal dysfunction caused by targeted disruption of the frizzled-4 gene","volume":"21","author":"Y Wang","year":"2001","journal-title":"J Neurosci"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10456-009-9155-3","article-title":"Computer-aided quantification of retinal neovascularization","volume":"12","author":"A Stahl","year":"2009","journal-title":"Angiogenesis"},{"issue":"1","key":"ref43","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"LE Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10456-013-9374-5","article-title":"Neuronal sirtuin1 mediates retinal vascular regeneration in oxygen-induced ischemic retinopathy","volume":"16","author":"J Chen","year":"2013","journal-title":"Angiogenesis"},{"issue":"6","key":"ref45","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1167\/iovs.10-5176","article-title":"The mouse retina as an angiogenesis model","volume":"51","author":"A Stahl","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/02713689608995831","article-title":"The effect of postnatal growth retardation on abnormal neovascularization in the oxygen exposed neonatal rat","volume":"15","author":"JM Holmes","year":"1996","journal-title":"Curr Eye Res"},{"issue":"3","key":"ref47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1203\/PDR.0b013e3181973dc8","article-title":"Oxygen-induced retinopathy in mice: amplification by neonatal IGF-I deficit and attenuation by IGF-I administration","volume":"65","author":"S Vanhaesebrouck","year":"2009","journal-title":"Pediatr Res"},{"key":"ref48","first-page":"476","article-title":"Genetic variants of FZD4 and LRP5 genes in patients with advanced retinopathy of prematurity","volume":"19","author":"H Kondo","year":"2013","journal-title":"Mol Vis"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1523\/JNEUROSCI.3210-09.2010","article-title":"Norrin promotes vascular regrowth after oxygen-induced retinal vessel loss and suppresses retinopathy in mice","volume":"30","author":"A Ohlmann","year":"2010","journal-title":"J Neurosci"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1167\/iovs.12-10127","article-title":"Retinal vascular rescue of oxygen-induced retinopathy in mice by norrin","volume":"54","author":"CC Tokunaga","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"ref51","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archophthalmol.2010.72","article-title":"Final visual acuity results in the early treatment for retinopathy of prematurity study","volume":"128","author":"WV Good","year":"2010","journal-title":"Archives of ophthalmology"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jaapos.2012.10.022","article-title":"Clinical characteristics of children with severe visual impairment but favorable retinal structural outcomes from the Early Treatment for Retinopathy of Prematurity (ETROP) study","volume":"17","author":"RM Siatkowski","year":"2013","journal-title":"J AAPOS"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/archophthalmol.2010.360","article-title":"Visual field extent at 6 years of age in children who had high-risk prethreshold retinopathy of prematurity","volume":"129","author":"GE Quinn","year":"2011","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"ref54","first-page":"CD001693","article-title":"Peripheral retinal ablation for threshold retinopathy of prematurity in preterm infants","author":"CC Andersen","year":"2000","journal-title":"The Cochrane database of systematic reviews"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","article-title":"Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity","volume":"98","author":"SG Tahija","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"D Lepore","year":"2014","journal-title":"Ophthalmology"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaapos.2014.03.011","article-title":"Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser","volume":"18","author":"W Chen","year":"2014","journal-title":"J AAPOS"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jaapos.2013.12.009","article-title":"Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy","volume":"18","author":"A Henaine-Berra","year":"2014","journal-title":"J AAPOS"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/ICB.0b013e318285238e","article-title":"Delayed recurrent neovascularization and persistent avascular retina following intravitreal bevacizumab for retinopathy of prematurity","volume":"7","author":"S Mehta","year":"2013","journal-title":"Retinal cases & brief reports"},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaapos.2013.01.004","article-title":"Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab","volume":"17","author":"S Ittiara","year":"2013","journal-title":"J AAPOS"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","article-title":"Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity","volume":"56","author":"L Kong","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","article-title":"Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity","volume":"153","author":"T Sato","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"ref63","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","article-title":"Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?","volume":"91","author":"U Spandau","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"ref64","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jaapos.2011.11.002","article-title":"Bevacizumab (Avastin) for retinopathy of prematurity: wrong dose, wrong drug, or both?","volume":"16","author":"RL Avery","year":"2012","journal-title":"J AAPOS"},{"issue":"2","key":"ref65","doi-asserted-by":"crossref","first-page":"F170","DOI":"10.1136\/archdischild-2011-301148","article-title":"Are we there yet? Bevacizumab therapy for retinopathy of prematurity","volume":"98","author":"BA Darlow","year":"2013","journal-title":"Archives of disease in childhood Fetal and neonatal edition"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0158320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T02:42:44Z","timestamp":1589683364000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0158320"}},"subtitle":[],"editor":[{"given":"Jennifer L.","family":"Wilkinson-Berka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,4]]},"references-count":65,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0158320","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,4]]}}}